Rubicon Research Ltd (RRL) is an innovation-driven and R&D focused pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products concentrated in USA (~99.6% of 1QFY26 revenue). As of Jun'25, its product portfolio included 72 active Abbreviated New Drug Applications (ANDAs), 9 active New Drug Applications (NDAs) and 1 Over-the-Counter (OTC) monography listed with the United States Food & Drug Administration (USFDA), which includes 16 specialty products. During FY25, RRL held a market share of...